Search

Your search keyword '"Pinter, Matthias"' showing total 694 results
Start Over Author "Pinter, Matthias"
694 results on '"Pinter, Matthias"'

1. Von Willebrand Factor Antigen Improves Risk Stratification for Patients with a Diagnosis of Resectable Hepatocellular Carcinoma

Author

Pereyra, David, Mandorfer, Mattias, Santol, Jonas, Gregory, Lindsey, Koeditz, Christoph, Ortmayr, Gregor, Schuetz, Clara, Rumpf, Benedikt, Ammon, Daphni, Laengle, Johannes, Schwarz, Christoph, Jonas, Jan Philipp, Pinter, Matthias, Lindenlaub, Florian, Tamandl, Dietmar, Thiels, Cornelius, Warner, Susanne, Smoot, Rory, Truty, Mark, Kendrick, Michael, Nagorney, David, Cleary, Sean, Gruenberger, Thomas, Reiberger, Thomas, and Starlinger, Patrick

Published
2024
Full Text
View/download PDF

3. Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome

Author

Simbrunner, Benedikt, Villesen, Ida Falk, Scheiner, Bernhard, Paternostro, Rafael, Schwabl, Philipp, Stättermayer, Albert Friedrich, Marculescu, Rodrig, Pinter, Matthias, Quehenberger, Peter, Trauner, Michael, Karsdal, Morten, Lisman, Ton, Reiberger, Thomas, Leeming, Diana Julie, and Mandorfer, Mattias

Published
2023
Full Text
View/download PDF

4. Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma

Author

Stern, Louisa, Schmidt, Constantin, Kocheise, Lorenz, Joerg, Vincent, Casar, Christian, Walter, Aurélie, Drenth, Joost P.H., Papp, Maria, Gatselis, Nikolaos K., Zachou, Kalliopi, Pinter, Matthias, Scheiner, Bernhard, Vogel, Arndt, Kirstein, Martha M., Finkelmeier, Fabian, Waidmann, Oliver, Weinmann, Arndt, Milkiewicz, Piotr, Thorburn, Douglas, Halliday, Neil, Lleo, Ana, Huber, Samuel, Dalekos, George N., Lohse, Ansgar W., Wege, Henning, von Felden, Johann, and Schulze, Kornelius

Published
2024
Full Text
View/download PDF

5. Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events

Author

Ben Khaled, Najib, Möller, Marie, Jochheim, Leonie S., Leyh, Catherine, Ehmer, Ursula, Böttcher, Katrin, Pinter, Matthias, Balcar, Lorenz, Scheiner, Bernhard, Weich, Alexander, Leicht, Hans Benno, Zarka, Valentina, Ye, Liangtao, Schneider, Julia, Piseddu, Ignazio, Öcal, Osman, Rau, Monika, Sinner, Friedrich, Venerito, Marino, Gairing, Simon Johannes, Förster, Friedrich, Mayerle, Julia, De Toni, Enrico N., Geier, Andreas, and Reiter, Florian P.

Published
2024
Full Text
View/download PDF

6. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

Author

Vithayathil, Mathew, D’Alessio, Antonio, Fulgenzi, Claudia Angela Maria, Nishida, Naoshi, Schönlein, Martin, von Felden, Johann, Schulze, Kornelius, Wege, Henning, Saeed, Anwaar, Wietharn, Brooke, Hildebrand, Hannah, Wu, Linda, Ang, Celina, Marron, Thomas U., Weinmann, Arndt, Galle, Peter R., Bettinger, Dominik, Bengsch, Bertram, Vogel, Arndt, Balcar, Lorenz, Scheiner, Bernhard, Lee, Pei-Chang, Huang, Yi-Hsiang, Amara, Suneetha, Muzaffar, Mahvish, Naqash, Abdul Rafeh, Cammarota, Antonella, Zanuso, Valentina, Pressiani, Tiziana, Pinter, Matthias, Cortellini, Alessio, Kudo, Masatoshi, Rimassa, Lorenza, Pinato, David J., and Sharma, Rohini

Published
2023
Full Text
View/download PDF

8. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

Author

Celsa, Ciro, Cabibbo, Giuseppe, Fulgenzi, Claudia A.M., Scheiner, Bernhard, D’Alessio, Antonio, Manfredi, Giulia F., Nishida, Naoshi, Ang, Celina, Marron, Thomas U., Saeed, Anwaar, Wietharn, Brooke, Pinter, Matthias, Cheon, Jaekyung, Huang, Yi-Hsiang, Lee, Pei-Chang, Phen, Samuel, Gampa, Anuhya, Pillai, Anjana, Vivaldi, Caterina, Salani, Francesca, Masi, Gianluca, Roehlen, Natascha, Thimme, Robert, Vogel, Arndt, Schönlein, Martin, von Felden, Johann, Schulze, Kornelius, Wege, Henning, Galle, Peter R., Kudo, Masatoshi, Rimassa, Lorenza, Singal, Amit G., El Tomb, Paul, Ulahannan, Susanna, Parisi, Alessandro, Chon, Hong Jae, Hsu, Wei-Fan, Stefanini, Bernardo, Verzoni, Elena, Giusti, Raffaele, Veccia, Antonello, Catino, Annamaria, Aprile, Giuseppe, Guglielmini, Pamela Francesca, Di Napoli, Marilena, Ermacora, Paola, Antonuzzo, Lorenzo, Rossi, Ernesto, Verderame, Francesco, Zustovich, Fable, Ficorella, Corrado, Di Pietro, Francesca Romana, Battelli, Nicola, Negrini, Giorgia, Grossi, Francesco, Bordonaro, Roberto, Pipitone, Stefania, Banzi, Maria, Ricciardi, Serena, Laera, Letizia, Russo, Antonio, De Giorgi, Ugo, Cavanna, Luigi, Sorarù, Mariella, Montesarchio, Vincenzo, Bordi, Paola, Brunetti, Leonardo, Pinto, Carmine, Bersanelli, Melissa, Cammà, Calogero, Cortellini, Alessio, and Pinato, David J.

Published
2024
Full Text
View/download PDF

9. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma

Author

Balcar, Lorenz, Scheiner, Bernhard, Fulgenzi, Claudia Angela Maria, D’Alessio, Antonio, Pomej, Katharina, Roig, Marta Bofill, Meyer, Elias Laurin, Che, Jaekyung, Nishida, Naoshi, Lee, Pei-Chang, Wu, Linda, Ang, Celina, Krall, Anja, Saeed, Anwaar, Stefanini, Bernardo, Cammarota, Antonella, Pressiani, Tiziana, Abugabal, Yehia I., Chamseddine, Shadi, Wietharn, Brooke, Parisi, Alessandro, Huang, Yi-Hsiang, Phen, Samuel, Vivaldi, Caterina, Salani, Francesca, Masi, Gianluca, Bettinger, Dominik, Vogel, Arndt, von Felden, Johann, Schulze, Kornelius, Silletta, Marianna, Trauner, Michael, Samson, Adel, Wege, Henning, Piscaglia, Fabio, Galle, Peter R., Stauber, Rudolf, Kudo, Masatoshi, Singal, Amit G., Itani, Aleena, Ulahannan, Susanna V., Parikh, Neehar D., Cortellini, Alessio, Kaseb, Ahmed, Rimassa, Lorenza, Chon, Hong Jae, Pinato, David J., and Pinter, Matthias

Published
2024
Full Text
View/download PDF

11. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study

Author

Allende, Daniela S, Amaddeo, Giuliana, Argemi, Josepmaria, Baulande, Sylvain, Beaufrère, Aurélie, Bermúdez-Ramos, María, Boulagnon-Rombi, Camille, Boursier, Jérôme, Bruges, Léa, Calderaro, Julien, Campani, Claudia, Caruso, Stefano, Casadei-Gardini, Andrea, Castano Garcia, Andres, Chan, Stephen Lam, D'Alessio, Antonio, Di Tommaso, Luca, Diaz, Alba, Digklia, Antonia, Dufour, Jean-François, Garcia-Porrero, Guillermo, Ghaffari Laleh, Narmin, Gnemmi, Viviane, Gopal, Purva, Graham, Rondell P., Heurgué, Alexandra, Iavarone, Massimo, Iñarrairaegui, Mercedes, Kather, Jakob Nikolas, Klein, Christophe, Labgaa, Ismail, Lameiras, Sonia, Legoix, Patricia, Lequoy, Marie, Leung, Howard Ho-Wai, Loménie, Nicolas, Maggioni, Marco, Maille, Pascale, Marín-Zuluaga, Juan Ignacio, Mendoza-Pacas, Guillermo, Michalak, Sophie, Mínguez, Beatriz, El Nahhas, Omar S M, Nault, Jean-Charles, Navale, Pooja, Ningarhari, Massih, Paradis, Valérie, Park, Young Nyun, Pawlotsky, Jean-Michel, Pedica, Federica, Perbellini, Riccardo, Peter, Simon, Pinato, David James, Pinter, Matthias, Radu, Pompilia, Regnault, Hélène, Reig, Maria, Rela, Mohamed, Rhee, Hyungjin, Rimassa, Lorenza, Rimini, Margherita, Salcedo, María Teresa, Sangro, Bruno, Scheiner, Bernhard, Sempoux, Christine, Su, Tung-Hung, Torres, Callie, Tran, Nguyen H, Trépo, Eric, Varela, Maria, Verset, Gontran, Vij, Mukul, Vogel, Arndt, Wendum, Dominique, Zeng, Qinghe, and Ziol, Marianne

Published
2023
Full Text
View/download PDF

12. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Author

Thompson, Alexander, Danta, Mark, Poursoltan, Pirooz, Kiberu, Andrew, Chittajallu, Renuka, Sood, Siddarth, Stauber, Rudolf, Pinter, Matthias, Peck-Radosavljevic, Markus, Decaestecker, Jochen, Cuyle, Pieter-Jan, Verset, Gontran, Van Vlierberghe, Hans, De Azevedo, Sergio, Andrade, Livia, Cunha Júnior, Ademar, Faria, Luiza, Yen, Cheng Tzu, Colli, Leandro, Asselah, Jamil, Kavan, Petr, Marquez, Vladimir, Brahmania, Mayur, Li, Qiang, Xing, Baocai, Guo, Yabing, Chen, Zhendong, Zhao, Haitao, Peng, Tao, Wang, Liming, Wang, Lu, Liu, Hongming, Wu, Feixiang, Qin, Lunxiu, Zheng, Qichang, Ying, Jieer, Li, Haitao, Wen, Tianfu, Qin, Shukui, Wen, Xiaoyu, Liu, Yunpeng, Chen, Minshan, Wang, Boqing, Bai, Yuxian, He, Yifu, Zhao, Hong, Zhou, Dong, Dai, Chaoliu, Teng, Gaojun, Cui, Shuzhong, Gao, Yi, Zhang, Xizhi, Lu, Zheng, Yin, Tao, Ding, Youming, Jia, Weidong, Xia, Yongxiang, Sun, Beicheng, Xia, Qiang, Yuan, Yufeng, Sun, Huichuan, Shi, Xuetao, Guzmán, Adrián, Corrales, Luis, Kral, Zdenek, Priester, Peter, Kubala, Eugen, Blanc, Jean Frederic, Bourliere, Marc, Peron, Jean Marie, Borg, Christophe, Bronowicki, Jean-Pierre, Ganne, Nathalie, Decaens, Thomas, Uguen, Thomas, Heurgue, Alexandra, Trojan, Joerg, Gonzalez-Carmona, Maria Angeles, Roderburg, Christoph, Ettrich, Thomas, Schotten, Clemens, Kandulski, Arne, Yau, Thomas, Chan, Lam, Scartozzi, Mario, Masi, Gianluca, Fanello, Silvia, Battezzati, Pier Maria, Leonardi, Francesco, Ghidini, Michele, Numata, Kazushi, Morimoto, Manabu, Hidaka, Hisashi, Tsuchiya, Kaoru, Yamashita, Tatsuya, Kato, Naoya, Kudo, Masatoshi, Hagihara, Atsushi, Koga, Hironori, Arakawa, Tomohiro, Nakamura, Ikuo, Kawamura, Yusuke, Kawaoka, Tomokazu, Shimada, Mitsuo, Hasegawa, Kiyoshi, Marusawa, Hiroyuki, Nakamura, Shinchiro, Hiraoka, Atsushi, Hayashi, Hiromitsu, Takeda, Shin, Lee, Han Chu, Paik, Seung Woon, Kim, Do Young, Lee, Jung Il, Jeong, Sook-Hyang, Kim, Won, Tak, Won Young, Heo, Jeong, Kim, Hyeyeong, Chon, Hong Jae, Cheong, Jaeyoun, Yoon, Seung Kew, Yoon, Jung-Hwan, Villalobos, Ricardo, Martinez Rodriguez, Jorge Luis, Oyervides Juarez, Victor, Hernández, Carlos Alberto, Klumpen, Heinz-Josef, de Vos-Geelen, Judith, Gane, Edward, Montenegro, Paola, Torres Mattos, Cesar, Janczewska, Ewa, Kawecki, Maciej, Nowakowska-Zajdel, Ewa, Fedenko, Alexander, Granov, Dmitrii, Alyasova, Anna, Sekacheva, Marina, Ledin, Evgeny, Samol, Jens, Toh, Han Chong, Calvo Campos, Mariona, Gomez Martin, Carlos, Lopez Lopez, Carlos, Muñoz Martin, Andres Jesus, Calleja Panero, Jose Luis, Montero Alvarez, Jose Luis, Reig Monzón, Maria, Delgado Mingorance, Ignacio, Minguez Rosique, Beatriz, Cheng, Ann Lii, Huang, Yi-Hsiang, Lin, Shi-Ming, Huang, Jee-Fu, Yu, Ming-Lung, Su, Wei-Wen, Korphaisarn, Krittiya, Maneenil, Kunlatida, Samdaengpan, Chayanee, Tharavichitkul, Ekkapong, Ozguroglu, Mustafa, Kose, Fatih, Harputluoglu, Hakan, Buchschacher, Gary, Thuluvath, Paul, Xiong, Henry, Patel, Mital, Gold, Philip, Li, Daneng, Brooks, Gabriel, Masood, Ashiq, Patel, Reema, George, Ben, Salgia, Reena, Manji, Gulam, Crow, Mary, Kaseb, Ahmed, Dugan, Matthew, Kadakia, Kunal, Kardosh, Adel, Gibbs, John, Shah, Ashesh, Burris III, Howard, Hsiehchen, David, Cheng, Ann-Lii, Kaseb, Ahmed O, Yopp, Adam C, Zhou, Jian, Nakamura, Shinichiro, Cha, Edward, Hack, Stephen P, Lian, Qinshu, Ma, Ning, Spahn, Jessica H, Wang, Yulei, Wu, Chun, and Chow, Pierce K H

Published
2023
Full Text
View/download PDF

17. Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma

Author

Pinato, David J., Li, Xiaoxue, Mishra-Kalyani, Pallavi, D’Alessio, Antonio, Fulgenzi, Claudia A.M., Scheiner, Bernhard, Pinter, Matthias, Wei, Guo, Schneider, Julie, Rivera, Donna R., Pazdur, Richard, Theoret, Marc R., Casak, Sandra, Lemery, Steven, Fashoyin-Aje, Lola, Cortellini, Alessio, and Pelosof, Lorraine

Published
2023
Full Text
View/download PDF

20. Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma

Author

Scheiner, Bernhard, Roessler, Daniel, Phen, Samuel, Lim, Mir, Pomej, Katharina, Pressiani, Tiziana, Cammarota, Antonella, Fründt, Thorben W., von Felden, Johann, Schulze, Kornelius, Himmelsbach, Vera, Finkelmeier, Fabian, Deibel, Ansgar, Siebenhüner, Alexander R., Shmanko, Kateryna, Radu, Pompilia, Schwacha-Eipper, Birgit, Ebert, Matthias P., Teufel, Andreas, Djanani, Angela, Hucke, Florian, Balcar, Lorenz, Philipp, Alexander B., Hsiehchen, David, Venerito, Marino, Sinner, Friedrich, Trauner, Michael, D'Alessio, Antonio, Fulgenzi, Claudia A.M., Pinato, David J., Peck-Radosavljevic, Markus, Dufour, Jean-François, Weinmann, Arndt, Kremer, Andreas E., Singal, Amit G., De Toni, Enrico N., Rimassa, Lorenza, and Pinter, Matthias

Published
2023
Full Text
View/download PDF

21. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.

Author

Galle, Peter Robert, primary, Decaens, Thomas, additional, Kudo, Masatoshi, additional, Qin, Shukui, additional, Fonseca, Leonardo, additional, Sangro, Bruno, additional, Karachiwala, Hatim, additional, Park, Joong-Won, additional, Gane, Edward, additional, Pinter, Matthias, additional, Tai, David, additional, Santoro, Armando, additional, Pizarro, Gonzalo, additional, Chiu, Chang-Fang, additional, Schenker, Michael, additional, He, Aiwu Ruth, additional, Wang, Qi, additional, Stromko, Caitlyn, additional, Hreiki, Joseph, additional, and Yau, Thomas, additional

Published
2024
Full Text
View/download PDF

22. SAT-105 Neutrophil extracellular traps are not linked to the development of decompensation, ACLF, or death in clinically stable patients with advanced chronic liver disease

Author

Balcar, Lorenz, primary, Scheiner, Bernhard, additional, Simbrunner, Benedikt, additional, Jachs, Mathias, additional, Hartl, Lukas, additional, Semmler, Georg, additional, Hofer, Benedikt, additional, Dominik, Nina, additional, Schwarz, Michael, additional, Friedrich Stättermayer, Albert, additional, Pinter, Matthias, additional, Trauner, Michael, additional, Reiberger, Thomas, additional, Lisman, Ton, additional, and Mandorfer, Mattias, additional

Published
2024
Full Text
View/download PDF

23. THU-464 aMAP score predicts progression-free survival in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

Author

Vithayathil, Mathew, primary, D'Alessio, Antonio, additional, Fulgenzi, Claudia, additional, Celsa, Ciro, additional, Manfredi, Giulia, additional, Nishida, Naoshi, additional, Schoenlein, Martin, additional, von Felden, Johann, additional, Schulze, Kornelius, additional, Wege, Henning, additional, Saeed, Anwaar, additional, Wietharn, Brooke, additional, Hildebrand, Hannah, additional, Wu, Linda, additional, Ang, Celina, additional, Marron, Thomas U., additional, Weinmann, Arndt, additional, Galle, Peter R., additional, Bettinger, Dominik, additional, Lin, Chun-yen, additional, Vogel, Arndt, additional, Scheiner, Bernhard, additional, Lee, Pei-Chang, additional, Huang, Yi-Hsiang, additional, Amara, Suneetha, additional, Muzaffar, Mahvish, additional, Naqash, Abdul Rafeh, additional, Zanuso, Valentina, additional, Pressiani, Tiziana, additional, Cabibbo, Giuseppe, additional, Dalbeni, Andrea, additional, Pinter, Matthias, additional, Singal, Amit, additional, Chon, Hong Jae, additional, Cortellini, Alessio, additional, Kudo, Masatoshi, additional, Rimassa, Lorenza, additional, Pinato, David J., additional, and Sharma, Rohini, additional

Published
2024
Full Text
View/download PDF

24. WED-171 Spleen stiffness and VWF-based non-invasive tests reflect severity of prehepatic and presinusoidal portal hypertension

Author

Balcar, Lorenz, primary, Semmler, Georg, additional, Schwarz, Michael, additional, Dominik, Nina, additional, Hofer, Benedikt, additional, Stopfer, Katharina, additional, Schedlbauer, Anna, additional, Hopp, Can, additional, Bauer, David, additional, Hartl, Lukas, additional, Jachs, Mathias, additional, Simbrunner, Benedikt, additional, Stättermayer, Albert Friedrich, additional, Mozayani, Behrang, additional, Pinter, Matthias, additional, Trauner, Michael, additional, Mandorfer, Mattias, additional, Reiberger, Thomas, additional, and Scheiner, Bernhard, additional

Published
2024
Full Text
View/download PDF

25. THU-075-YI Incidence and prognostic value of zinc and seleniumdeficiency in cirrhosis

Author

Dominik, Nina, primary, Balcar, Lorenz, additional, Semmler, Georg, additional, Simbrunner, Benedikt, additional, Schwarz, Michael, additional, Hofer, Benedikt, additional, Hartl, Lukas, additional, Jachs, Mathias, additional, Scheiner, Bernhard, additional, Pinter, Matthias, additional, Trauner, Michael, additional, Mandorfer, Mattias, additional, Pilger, Alexander, additional, and Reiberger, Thomas, additional

Published
2024
Full Text
View/download PDF

26. THU-471-YI From randomised clinical trials to clinical practice: a systematic reviewand meta-analysis of real-word data on atezolizumab plus bevacizumab for advanced hepatocellular carcinoma

Author

Manfredi, Giulia Francesca, primary, Fulgenzi, Claudia, additional, Celsa, Ciro, additional, Stefanini, Bernardo, additional, D'Alessio, Antonio, additional, Pinter, Matthias, additional, Scheiner, Bernhard, additional, Awosika, Nichola, additional, Huang, Yi-Hsiang, additional, Lin, Chun-yen, additional, Dalbeni, Andrea, additional, Vogel, Arndt, additional, Galle, Peter R., additional, Kudo, Masatoshi, additional, Rimassa, Lorenza, additional, Chon, Hong Jae, additional, Cabibbo, Giuseppe, additional, Piscaglia, Fabio, additional, Camma, Calogero, additional, Pillai, Anjana, additional, Pirisi, Mario, additional, Singal, Amit, additional, and Pinato, David J., additional

Published
2024
Full Text
View/download PDF

28. TOP-488-YI Fecal microbiota transplant combined with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma who progressed on atezolizumab plus bevacizumab-interim analysis of the FAB-HCC phase II pilot study

Author

Pomej, Katharina, primary, Frick, Adrian, additional, Scheiner, Bernhard, additional, Balcar, Lorenz, additional, Pajancic, Larissa, additional, Klotz, Anton, additional, Regnat, Katharina, additional, Zinober, Kerstin, additional, Trauner, Michael, additional, Tamandl, Dietmar, additional, Gasche, Christoph, additional, and Pinter, Matthias, additional

Published
2024
Full Text
View/download PDF

29. OS-112-YI Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapybased systemic therapy

Author

Scheiner, Bernhard, primary, Kang, Beodeul, additional, Balcar, Lorenz, additional, Radu, Pompilia, additional, Reiter, Florian P, additional, Adžić, Gordan, additional, Guo, Jiang, additional, Gao, Xu, additional, Yuan, Xiao, additional, Cheng, Long, additional, Gorgulho, Joao, additional, Schultheiß, Michael, additional, Khaled, Najib Ben, additional, Sinner, Friedrich, additional, D'Alessio, Antonio, additional, Pomej, Katharina, additional, Saborowski, Anna, additional, Schwacha-Eipper, Birgit, additional, Zarka, Valentina, additional, Lampichler, Katharina, additional, Nishida, Naoshi, additional, Lee, Pei-Chang, additional, Krall, Anja, additional, Saeed, Anwaar, additional, Himmelsbach, Vera, additional, Tesini, Giulia, additional, Wietharn, Brooke, additional, Huang, Yi-Hsiang, additional, Vivaldi, Caterina, additional, Masi, Gianluca, additional, Vogel, Arndt, additional, Schulze, Kornelius, additional, Trauner, Michael, additional, Stauber, Rudolf E., additional, Kudo, Masatoshi, additional, Dekervel, Jeroen, additional, Parikh, Neehar, additional, Dufour, Jean-François, additional, Prejac, Juraj, additional, Geier, Andreas, additional, Bengsch, Bertram, additional, von Felden, Johann, additional, Venerito, Marino, additional, Philipp, Alexander, additional, Finkelmeier, Fabian, additional, Ji, Fanpu, additional, Wang, Hung-Wei, additional, Rimassa, Lorenza, additional, Pinato, David J., additional, Bouattour, Mohamed, additional, Chon, Hong Jae, additional, and Pinter, Matthias, additional

Published
2024
Full Text
View/download PDF

30. OS-027-YI Immune checkpoint profiles on circulating extracellular vesicles predict response to immunotherapy in heptaocellular carcinoma

Author

Masood, Ramsha, primary, Buescher, Gustav, additional, Gorgulho, Joao, additional, Giehren, Franziska, additional, Pagani, Francesca, additional, Kocheise, Lorenz, additional, Jörg, Vincent, additional, Schmidt, Constantin, additional, Adlung, Lorenz, additional, Waldmann, Moritz, additional, Renne, Thomas, additional, Krause, Jenny, additional, Sauter, Guido, additional, Ricklefs, Franz, additional, Maire, Cecile, additional, Shafiq, Mohsin, additional, Lohse, Ansgar W., additional, Huber, Samuel, additional, Wege, Henning, additional, Zimpel, Carolin, additional, Marquardt, Jens U., additional, Scheiner, Bernhard, additional, Balcar, Lorenz, additional, Pinter, Matthias, additional, de Toni, Enrico, additional, Piseddu, Ignazio, additional, Khaled, Najib Ben, additional, Schulze, Kornelius, additional, and von Felden, Johann, additional

Published
2024
Full Text
View/download PDF

31. Alpha-1 antitrypsin Pi∗Z allele is an independent risk factor for liver transplantation and death in patients with advanced chronic liver disease

Author

Balcar, Lorenz, Scheiner, Bernhard, Urheu, Markus, Weinberger, Patrick, Paternostro, Rafael, Simbrunner, Benedikt, Hartl, Lukas, Jachs, Mathias, Bauer, David, Semmler, Georg, Willheim, Claudia, Pinter, Matthias, Ferenci, Peter, Trauner, Michael, Reiberger, Thomas, Stättermayer, Albert Friedrich, and Mandorfer, Mattias

Published
2022
Full Text
View/download PDF

34. High histamine levels are associated with acute‐on‐chronic liver failure and liver‐related death in patients with advanced chronic liver disease.

Author

Schwarz, Michael, Simbrunner, Benedikt, Jachs, Mathias, Hartl, Lukas, Balcar, Lorenz, Bauer, David J. M., Semmler, Georg, Hofer, Benedikt S., Scheiner, Bernhard, Pinter, Matthias, Stättermayer, Albert F., Trauner, Michael, Reiberger, Thomas, and Mandorfer, Mattias

Subjects
VENOUS pressure, PORTAL hypertension, LIVER failure, SERUM albumin, HISTAMINE
Abstract

Background and Aims: The role of histamine in advanced chronic liver disease (ACLD) is poorly understood. We investigated plasma histamine levels across ACLD stages and their prognostic value. Methods: We included patients with evidence of ACLD, defined by portal hypertension (hepatic venous pressure gradient [HVPG] ≥6 mmHg) and/or a liver stiffness measurement by transient elastography ≥10 kPa, who underwent HVPG measurement between 2017 and 2020. Acute‐on‐chronic liver failure (ACLF) and/or liver‐related death were defined as composite endpoint. Results: Of 251 patients, 82.5% had clinically significant portal hypertension (median HVPG: 17 mmHg [interquartile range (IQR) 12–21]) and 135 patients (53.8%) were decompensated at baseline. Median plasma histamine was 8.5 nmol/L (IQR: 6.4–11.5), 37.1% of patients showed elevated values (>9.9 nmol/L). Histamine levels did not differ significantly across Child‐Turcotte‐Pugh (CTP) stages nor strata of model for end‐stage liver disease (MELD) or HVPG. Histamine levels correlated with markers of circulatory dysfunction (i.e. sodium, renin and aldosterone). During a median follow‐up of 29.2 months, 68 patients developed ACLF or liver‐related death. In univariate as well as in multivariate analysis (adjusting for age, sex, HVPG as well as either MELD, clinical stage, and serum albumin or CTP and serum sodium), elevated histamine levels remained associated with the composite endpoint. CTP‐based multivariate model adjusted sub‐distribution hazard ratio (asHR): 1.010 (95% CI: 1.004–1.021), p <.001; MELD‐based multivariate model asHR: 1.030 (95% CI: 1.017–1.040), p <.001. Conclusion: High levels of histamine were linked to circulatory dysfunction in ACLD patients and independently associated with increased risks of ACLF or liver‐related death. Further mechanistic studies on the link between histamine signalling and development of hyperdynamic circulation and ACLF are warranted. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Prevalence and prognostic value of zinc and selenium deficiency in advanced chronic liver disease.

Author

Dominik, Nina, Balcar, Lorenz, Semmler, Georg, Simbrunner, Benedikt, Schwarz, Michael, Hofer, Benedikt S., Hartl, Lukas, Jachs, Mathias, Scheiner, Bernhard, Pinter, Matthias, Trauner, Michael, Mandorfer, Mattias, Pilger, Alexander, and Reiberger, Thomas

Subjects
VENOUS pressure, TRACE elements, PROGNOSIS, INTERLEUKIN-6, LIVER diseases, ZINC, SELENIUM
Abstract

Summary: Background and Aims: Zinc and selenium are essential trace elements involved in important (patho)physiological processes. The prevalence and prognostic implications of zinc and selenium deficiency in patients with advanced chronic liver disease (ACLD) remain unknown. Methods: We determined serum zinc and selenium concentrations in 309 patients with ACLD undergoing hepatic venous pressure gradient (HVPG) measurement between 2019 and 2022. We evaluated the prevalence of zinc/selenium deficiency and assessed its association with severity of ACLD and liver‐related events (LRE, i.e. first/further hepatic decompensation/liver‐related death). Results: Among 309 ACLD patients (median: age: 57 [IQR: 50–64], MELD: 11 [IQR: 9–16], HVPG: 17 [IQR: 11–20]), 73% (227) and 63% (195) were deficient in zinc and selenium, respectively. Decompensated (dACLD) patients showed significantly lower serum zinc (median: 48 [IQR: 38–59] vs. compensated, cACLD: 65 [IQR: 54–78], p < 0.001) and selenium levels (median: 4.9 [IQR 4.0–6.2] vs. cACLD: 6.1 [IQR 5.1–7.3], p < 0.001). Significant correlations of zinc/selenium levels were found with MELD (zinc: ρ = −0.498, p < 0.001; selenium: ρ = −0.295, p < 0.001), HVPG (zinc: ρ = −0.400, p < 0.001; selenium: ρ = −0.157, p = 0.006) and liver disease‐driving mechanisms (IL6, bile‐acid homeostasis). On multivariable analysis, low zinc/selenium levels, age and MELD remained independently associated with LRE. Conclusion: Zinc and selenium deficiencies are common in ACLD patients especially with higher MELD and HVPG. Low zinc and selenium levels independently predicted hepatic decompensation and liver‐related death. The effect of zinc/selenium supplementation in ACLD should be investigated in future trials. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction.

Author

Fulgenzi, Claudia Angela Maria, Scheiner, Bernhard, D'Alessio, Antonio, Mehan, Aman, Manfredi, Giulia F., Celsa, Ciro, Nishida, Naoshi, Ang, Celina, Marron, Thomas U., Wu, Linda, Saeed, Anwaar, Wietharn, Brooke, Cammarota, Antonella, Pressiani, Tiziana, Pinter, Matthias, Sharma, Rohini, Cheon, Jaekyung, Huang, Yi-Hsiang, Lee, Pei-Chang, and Phen, Samuel

Published
2024
Full Text
View/download PDF

37. Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension

Author

Wöran, Katharina, Semmler, Georg, Jachs, Mathias, Simbrunner, Benedikt, Bauer, David Josef Maria, Binter, Teresa, Pomej, Katharina, Stättermayer, Albert Friedrich, Schwabl, Philipp, Bucsics, Theresa, Paternostro, Rafael, Lampichler, Katharina, Pinter, Matthias, Trauner, Michael, Mandorfer, Mattias, Stift, Judith, Reiberger, Thomas, and Scheiner, Bernhard

Published
2022
Full Text
View/download PDF

40. Von Willebrand factor for outcome prediction within different clinical stages of advanced chronic liver disease

Author

Dominik, Nina, primary, Scheiner, Bernhard, additional, Zanetto, Alberto, additional, Balcar, Lorenz, additional, Semmler, Georg, additional, Campello, Elena, additional, Schwarz, Michael, additional, Paternostro, Rafael, additional, Simbrunner, Benedikt, additional, Hofer, Benedikt S., additional, Stättermayer, Albert Friedrich, additional, Pinter, Matthias, additional, Trauner, Michael, additional, Quehenberger, Peter, additional, Simioni, Paolo, additional, Reiberger, Thomas, additional, and Mandorfer, Mattias, additional

Published
2024
Full Text
View/download PDF

43. Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease

Author

Simbrunner, Benedikt, Stadlmann, Alexander, Schwabl, Philipp, Paternostro, Rafael, Bauer, David J.M., Bucsics, Theresa, Scheiner, Bernhard, Lampichler, Katharina, Wöran, Katharina, Beer, Andrea, Eigenbauer, Ernst, Pinter, Matthias, Stättermayer, Albert-Friedrich, Marculescu, Rodrig, Szekeres, Thomas, Trauner, Michael, Mandorfer, Mattias, and Reiberger, Thomas

Published
2021
Full Text
View/download PDF

44. Evolution of liver function during immune checkpoint inhibitor treatment for hepatocellular carcinoma

Author

Pomej, Katharina, Balcar, Lorenz, Sidali, Sabrina, Sartoris, Riccardo, Meischl, Tobias, Trauner, Michael, Mandorfer, Mattias, Reiberger, Thomas, Ronot, Maxime, Bouattour, Mohamed, Pinter, Matthias, and Scheiner, Bernhard

Abstract

Deterioration of liver function is a leading cause of death in patients with advanced hepatocellular carcinoma (HCC). We evaluated the impact of immune checkpoint inhibitor (ICI)‐treatment on liver function and outcomes. HCC patients receiving ICIs or sorafenib between 04/2003 and 05/2024 were included. Liver function (assessed by Child‐Pugh score [CPS]) was evaluated at the start of ICI‐treatment (baseline, BL) and 3 and 6 months thereafter. A ≥1 point change in CPS was defined as deterioration(−) or improvement(+), while equal CPS points were defined as stable(=). Overall, 182 ICI‐treated patients (66.8 ± 11.8 years; cirrhosis: n= 134, 74%) were included. At BL, median CPS was 5 (IQR: 5–6; CPS‐A: 147, 81%). After 3 months, liver function improved/stabilized in 102 (56%) and deteriorated in 61 (34%) patients, while 19 (10%) patients deceased/had missing follow‐up (d/noFU). Comparable results were observed at 6 months (+/=: n= 82, 45%; −: n= 55, 30%; d/noFU: n= 45, 25%). In contrast, 54 (34%) and 33 (21%) out of 160 sorafenib patients achieved improvement/stabilization at 3 and 6 months, respectively. Radiological response was linked to CPS improvement/stabilization at 6 months (responders vs. non‐responders, 73% vs. 50%; p= 0.007). CPS improvement/stabilization at 6 months was associated with better overall survival following landmark analysis (6 months: +/=: 28.4 [95% CI: 18.7–38.1] versus −: 14.2 [95% CI: 10.3–18.2] months; p< 0.001). Of 35 ICI‐patients with CPS‐B at BL, improvement/stabilization occurred in 16 (46%) patients, while 19 (54%) patients deteriorated/d/noFU at 3 months. Comparable results were observed at 6 months (CPS +/=: 14, 40%, −: 8, 23%). Importantly, 6/35 (17%) and 9/35 (26%) patients improved from CPS‐B to CPS‐A at 3 and 6 months. Radiological response to ICI‐treatment was associated with stabilization or improvement in liver function, which correlated with improved survival, even in patients with Child‐Pugh class B at baseline.

Published
2024
Full Text
View/download PDF

45. NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Author

Pfister, Dominik, Núñez, Nicolás Gonzalo, Pinyol, Roser, Govaere, Olivier, Pinter, Matthias, Szydlowska, Marta, Gupta, Revant, Qiu, Mengjie, Deczkowska, Aleksandra, Weiner, Assaf, Muller, Florian, Sinha, Ankit, Friebel, Ekaterina, Engleitner, Thomas, Lennggenhager, Daniela, Moncsek, Anja, and Heide, Danijela

Subjects
Fatty liver -- Complications and side effects, Immunotherapy -- Methods, Patient monitoring -- Methods, Hepatoma -- Care and treatment -- Causes of, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Hepatocellular carcinoma (HCC) can have viral or non-viral causes.sup.1-5. Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification of patients for optimal response to therapy is an unmet need.sup.6,7. Here we report the progressive accumulation of exhausted, unconventionally activated CD8.sup.+PD1.sup.+ T cells in NASH-affected livers. In preclinical models of NASH-induced HCC, therapeutic immunotherapy targeted at programmed death-1 (PD1) expanded activated CD8.sup.+PD1.sup.+ T cells within tumours but did not lead to tumour regression, which indicates that tumour immune surveillance was impaired. When given prophylactically, anti-PD1 treatment led to an increase in the incidence of NASH-HCC and in the number and size of tumour nodules, which correlated with increased hepatic CD8.sup.+PD1.sup.+CXCR6.sup.+, TOX.sup.+, and TNF.sup.+ T cells. The increase in HCC triggered by anti-PD1 treatment was prevented by depletion of CD8.sup.+ T cells or TNF neutralization, suggesting that CD8.sup.+ T cells help to induce NASH-HCC, rather than invigorating or executing immune surveillance. We found similar phenotypic and functional profiles in hepatic CD8.sup.+PD1.sup.+ T cells from humans with NAFLD or NASH. A meta-analysis of three randomized phase III clinical trials that tested inhibitors of PDL1 (programmed death-ligand 1) or PD1 in more than 1,600 patients with advanced HCC revealed that immune therapy did not improve survival in patients with non-viral HCC. In two additional cohorts, patients with NASH-driven HCC who received anti-PD1 or anti-PDL1 treatment showed reduced overall survival compared to patients with other aetiologies. Collectively, these data show that non-viral HCC, and particularly NASH-HCC, might be less responsive to immunotherapy, probably owing to NASH-related aberrant T cell activation causing tissue damage that leads to impaired immune surveillance. Our data provide a rationale for stratification of patients with HCC according to underlying aetiology in studies of immunotherapy as a primary or adjuvant treatment. In hepatocellular carcinoma driven by non-alcoholic steatohepatitis, aberrant T cell activation and impaired immune surveillance seem to make hepatocellular carcinoma less responsive to anti-PD1 or anti-PDL1 immunotherapy., Author(s): Dominik Pfister [sup.1] [sup.82] , Nicolás Gonzalo Núñez [sup.2] , Roser Pinyol [sup.3] , Olivier Govaere [sup.4] , Matthias Pinter [sup.5] [sup.6] , Marta Szydlowska [sup.1] , Revant Gupta [...]

Published
2021
Full Text
View/download PDF

47. Systemic Treatment of Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Multicenter Trial.

Author

Himmelsbach, Vera, Jeschke, Matthias, Lange, Christian M., Scheiner, Bernhard, Pinter, Matthias, Sinner, Friedrich, Venerito, Marino, Queck, Alexander, Trojan, Jörg, Waidmann, Oliver, and Finkelmeier, Fabian

Subjects
PREVENTION of surgical complications, CANCER relapse, STATISTICAL significance, PROTEIN-tyrosine kinase inhibitors, LOGISTIC regression analysis, RETROSPECTIVE studies, SORAFENIB, DESCRIPTIVE statistics, KAPLAN-Meier estimator, LOG-rank test, DRUG efficacy, RESEARCH, MEDICAL records, ACQUISITION of data, SURVIVAL analysis (Biometry), CONFIDENCE intervals, PROGRESSION-free survival, DATA analysis software, HEPATOCELLULAR carcinoma, LIVER transplantation, IMMUNOSUPPRESSION, OVERALL survival, PROPORTIONAL hazards models
Abstract

Simple Summary: Liver transplant is an approach for the curative treatment of early stage hepatocellular carcinoma and the often underlying liver cirrhosis. However, a recurrence of the cancer is to be expected in 10 to 20% of cases after liver transplantation. The treatment of recurrent hepatocellular carcinoma remains difficult, as immunotherapy is usually not recommended for systemic treatment after transplantation. Therefore, it is often necessary to resort to tyrosine kinase inhibitors in advanced stage hepatocellular carcinoma. This multicenter trial aims at assessing the effect of tyrosine kinase inhibitors and immunosuppression on the outcome of patients with recurrent hepatocellular carcinoma after liver transplantation. Introduction: The tyrosine kinase inhibitors (TKIs) sorafenib and lenvatinib represent the first-line systemic therapy of choice for patients with hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT). Under sorafenib and lenvatinib, HCC patients have shown increasingly improved overall survival in clinical studies over the years. In contrast, data on overall survival for patients with HCC recurrence after LT under TKIs are scarce and limited to small retrospective series. In this retrospective, multicenter study, we investigated the efficacy of TKI therapy and the influence of immunosuppression in patients with HCC recurrence after LT. Methods: Retrospective data were collected from four transplant centers from Germany and Austria. We included patients with HCC recurrence after LT between 2007 and 2020 who were treated with a TKI. Results: In total, we analyzed data from 46 patients with HCC recurrence after LT. The most common underlying liver disease was hepatitis C, accounting for 52.2%. The median time to relapse was 11.8 months (range 0–117.7 months). The liver graft was affected in 21 patients (45.7%), and 36 patients (78.3%) had extrahepatic metastases at initial diagnosis of recurrence, with the lung being the most commonly affected (n = 25, 54.3%). Of the total, 54.3% (n = 25) of the patients were initially treated locally; 39 (85.8%) and 7 (15.2%) patients received sorafenib and lenvatinib, respectively, as first-line systemic therapy. Median overall survival of the whole cohort was 10.9 months (95% confidence interval (95% CI) 6.9–14.9 months) and median progression free survival was 5.7 months (95% CI 2.0–9.4 months) from treatment initiation. Conclusion: Since history of liver transplantation is considered a contraindication for immunotherapy, prognosis of patients with HCC recurrence after LT remains poor. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. Analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) and Child–Pugh (CP)-B liver function treated with regorafenib in routine clinical practice in the observational REFINE study.

Author

Kim, Yoon Jun, primary, Merle, Philippe, additional, Finn, Richard S., additional, Kudo, Masatoshi, additional, Klümpen, Heinz-Josef, additional, Lim, Ho Yeong, additional, Pinter, Matthias, additional, Babajanyan, Svetlana, additional, Khan, Javeed, additional, Awan, Maria, additional, Özgürdal, Kirhan, additional, and Qin, Shukui, additional

Published
2024
Full Text
View/download PDF

49. Initial uptake of durvalumab with or without tremelimumab for advanced hepatocellular carcinoma in routine clinical practice: Preliminary results of the international DT-real study.

Author

Celsa, Ciro, primary, Nishida, Naoshi, additional, Arvind, Ashwini, additional, Ulahannan, Susanna Varkey, additional, Li, Michael, additional, Scheiner, Bernhard, additional, Fulgenzi, Claudia A.M., additional, D'Alessio, Antonio, additional, Manfredi, Giulia F, additional, Stefanini, Bernardo, additional, Cabibbo, Giuseppe, additional, Cortellini, Alessio, additional, Pinter, Matthias, additional, Kelley, Robin Kate, additional, El Tomb, Paul Antoine, additional, Singal, Amit G., additional, Kudo, Masatoshi, additional, and Pinato, David James, additional

Published
2024
Full Text
View/download PDF

50. Efficacy of immune checkpoint inhibitors in patients with HIV-associated unresectable HCC (uHCC): Propensity-score matched analyses from two international consortia.

Author

Fulgenzi, Claudia A.M., primary, El Zarif, Talal, additional, Nassar, Amin, additional, Adib, Elio, additional, Bellmunt, Joaquim, additional, Marron, Thomas Urban, additional, Lorentsen, Michael, additional, McKay, Rana R., additional, Baena, Javier, additional, Ang, Celina, additional, Rimassa, Lorenza, additional, Kudo, Masatoshi, additional, Parisi, Alessandro, additional, Saeed, Anwaar, additional, Lee, Pei-Chang, additional, Parikh, Neehar, additional, Pinter, Matthias, additional, Cortellini, Alessio, additional, Naqash, Abdul Rafeh, additional, and Pinato, David James, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results